Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Saneron CCEL Therapeutics, an affiliate of US-based private cord blood bank Cryo-Cell International, and the University of South Florida have received a patent for processing umbilical cord blood for therapeutic use against various diseases.
Subscribe to our email newsletter
The new patent covers the method of retrieval, incubation and transplantation of cells derived from umbilical cord blood.
The processed cells can be used to treat neurodegenerative diseases, including Parkinson’s disease, Huntington’s disease, multiple sclerosis and Alzheimer’s, in addition to spinal cord and brain injuries.
The patented method has the potential to treat heart attacks and cardiovascular diseases as well.
Saneron president and COO Nicole Kuzmin-Nichols said, "Umbilical cord blood stem cells provide an advantage over stem cells derived from bone marrow because they are easier to obtain."
Cryo-Cell is a major investor in Florida-based Saneron CCEL Therapeutics.
Cryo-Cell chairman and co-CEO David Portnoy said, "Our partnership with Saneron CCEL and the firm’s many talented researchers sets Cryo-Cell apart from most stem cell banks which focus on storage."